Authors
Latest:
Exploring Next-Line Options in HER2- MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Frontline Combination Therapy Intensification May Improve Survival in NSCLCHigher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Latest:
Yazeed Sawalha, MD, on Use of Autologous Stem Cell Transplant in Mantle Cell LymphomaYazeed Sawalha, MD, discusses how often autologous stem cell transplant is utilized in patients with mantle cell lymphoma.
Latest:
KRAS+ NSCLC: Treatment Management StrategiesThis video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.
Latest:
Patient Case Presentation: A 69-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Symptomatic Brain MetastasesPanelists discuss how a 69-year-old woman with newly diagnosed EGFR-mutant mNSCLC and symptomatic brain metastases requires immediate multidisciplinary care including steroids, radiation oncology consultation, and potential hospitalization, with treatment approach favoring stereotactic radiosurgery for dominant lesions followed by combination therapy like FLAURA2, while emphasizing that asymptomatic patients might allow for initial tyrosine kinase inhibitor treatment with close monitoring before considering radiation to potentially reduce treatment field and minimize long-term neurotoxicity.
Latest:
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case ReportHans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.
Latest:
Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025Panelists discuss key strides made in 2024, including exciting data presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024), and reflect on pivotal developments, such as new insights into Bruton tyrosine kinase inhibitors, that are shaping clinical practice while looking ahead to 2025 with anticipation for continued advancements that will further enhance treatment strategies and patient outcomes.
Latest:
PD-L1 Expression May Be Associated with Pathological Complete Response in TNBC“PD-L1 expression was significantly associated with pCR, which increased with higher PD-L1 expression on immune cells,” said Giampaolo Bianchini, an author of the NeoTRIPaPDL1 study.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Increased Survival With Initial Lenvantinib in Hepatocellular CarcinomaA multicenter study found that using lenvatinib for initial treatment helped to increase survival in patients with stage B2 hepatocellular carcinoma.
Latest:
Finding Ways to Break the Mold in GU OncologyLeaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Latest:
Julian Adams, PhD, on Innovating Bone Marrow Transplantation With Omidubicel in Hematologic MalignanciesJulian Adams, PhD, discusses the potential of Omidubicel for patients with hematologic cancers such as lymphomas and leukemias.
Latest:
Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug ConjugatesThis review article published in the journal ONCOLOGY® looks at the successful clinical development of immunotherapies, PARP inhibitors, and antibody-drug conjugates for the management of metastatic triple-negative breast cancer and how these have improved the survival outcome of patients. Over the coming years, therapeutic developments in precision medicine will likely change the treatment landscape and might make the current definition of triple-negative breast cancer as a disease that is estrogen receptor, progesterone receptor, and HER2 negative obsolete.
Latest:
Survival of Patients With Inoperable Non–Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation PneumonitisQianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.
Latest:
Ravi A. Madan, MD, Discusses the Significance of the PEACE-1 Trial With Docetaxel, Abiraterone, ADT, and Radiotherapy in mCSPCRavi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.
Latest:
Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIsDr. Judd W. Moul, MD, and colleagues present the case of a man, aged 73 years, with a prostate-specific antigen level of 110 ng/mL after 4 negative prostate biopsies and 4 negative prostate MRIs.
